Trials / Unknown
UnknownNCT05856578
Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes
Nanjing Medical University, Nanjing First Hospital
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the efficacy and safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Canagliflozin for 12 weeks in individuals with type 2 diabetes mellitus
Detailed description
To compare the clinical efficacy, insulin resistance and blood glucose fluctuation of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Canagliflozin in patients with type 2 diabetes mellitus using FGMS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mulberry Twig Alkaloid Tablet | Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid |
| DRUG | Canagliflozin | Canagliflozin 100mg po qd |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2023-05-31
- Completion
- 2023-12-31
- First posted
- 2023-05-12
- Last updated
- 2023-05-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05856578. Inclusion in this directory is not an endorsement.